Wim J. Tamminga

645 total citations
13 papers, 492 citations indexed

About

Wim J. Tamminga is a scholar working on Pharmacology, Pediatrics, Perinatology and Child Health and Economics and Econometrics. According to data from OpenAlex, Wim J. Tamminga has authored 13 papers receiving a total of 492 indexed citations (citations by other indexed papers that have themselves been cited), including 8 papers in Pharmacology, 7 papers in Pediatrics, Perinatology and Child Health and 3 papers in Economics and Econometrics. Recurrent topics in Wim J. Tamminga's work include Pharmacogenetics and Drug Metabolism (8 papers), Pharmaceutical studies and practices (5 papers) and Health Systems, Economic Evaluations, Quality of Life (3 papers). Wim J. Tamminga is often cited by papers focused on Pharmacogenetics and Drug Metabolism (8 papers), Pharmaceutical studies and practices (5 papers) and Health Systems, Economic Evaluations, Quality of Life (3 papers). Wim J. Tamminga collaborates with scholars based in Netherlands, Sweden and Germany. Wim J. Tamminga's co-authors include J. H. G. Jonkman, B. Oosterhuis, J. Wemer, Dick de Zeeuw, Jaap Wieling, Joachim Stangier, Lou de Leij, Sjoerd P. van Marle, Johan Wemer and L.F.M.H. de Leij and has published in prestigious journals such as British Journal of Clinical Pharmacology, European Journal of Clinical Pharmacology and The Journal of Clinical Pharmacology.

In The Last Decade

Wim J. Tamminga

12 papers receiving 472 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Wim J. Tamminga Netherlands 10 264 105 96 90 88 13 492
Deepak Gopal Shewade India 17 198 0.8× 106 1.0× 136 1.4× 132 1.5× 102 1.2× 68 708
SoJeong Yi South Korea 18 157 0.6× 110 1.0× 131 1.4× 100 1.1× 88 1.0× 45 705
D. A. Flockhart United States 9 283 1.1× 132 1.3× 62 0.6× 37 0.4× 68 0.8× 20 554
Chandrasekaran Adithan India 14 154 0.6× 81 0.8× 188 2.0× 80 0.9× 55 0.6× 27 597
William Schary United States 10 220 0.8× 89 0.8× 63 0.7× 45 0.5× 117 1.3× 26 623
M.E.G. Naranjo Spain 10 305 1.2× 114 1.1× 45 0.5× 34 0.4× 67 0.8× 12 425
Peter M. Krahn Saudi Arabia 6 217 0.8× 106 1.0× 46 0.5× 40 0.4× 61 0.7× 7 444
E. A. Sotaniemi Finland 9 204 0.8× 139 1.3× 58 0.6× 47 0.5× 103 1.2× 15 588
H.F. Woods United Kingdom 8 328 1.2× 130 1.2× 98 1.0× 77 0.9× 102 1.2× 9 708
Boo Edgar Sweden 11 195 0.7× 101 1.0× 129 1.3× 51 0.6× 116 1.3× 17 508

Countries citing papers authored by Wim J. Tamminga

Since Specialization
Citations

This map shows the geographic impact of Wim J. Tamminga's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Wim J. Tamminga with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Wim J. Tamminga more than expected).

Fields of papers citing papers by Wim J. Tamminga

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Wim J. Tamminga. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Wim J. Tamminga. The network helps show where Wim J. Tamminga may publish in the future.

Co-authorship network of co-authors of Wim J. Tamminga

This figure shows the co-authorship network connecting the top 25 collaborators of Wim J. Tamminga. A scholar is included among the top collaborators of Wim J. Tamminga based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Wim J. Tamminga. Wim J. Tamminga is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

13 of 13 papers shown
1.
Heuberger, Jules A. A. C., et al.. (2025). Sentinel dosing: A proposed algorithm to guide decision making on which cohorts in early phase clinical pharmacology trials should use this approach. British Journal of Clinical Pharmacology. 91(9). 2705–2710.
2.
3.
Daas, Izaak den, Johan Wemer, Wim J. Tamminga, et al.. (2012). Serial CSF sampling over a period of 30 h via an indwelling spinal catheter in healthy volunteers: headache, back pain, tolerability and measured acetylcholine profile. European Journal of Clinical Pharmacology. 69(5). 1083–1090. 8 indexed citations
4.
5.
Tamminga, Wim J., Johan Wemer, B. Oosterhuis, et al.. (2003). Polymorphic drug metabolism (CYP2D6) and utilisation of psychotropic drugs in hospitalised psychiatric patients: a retrospective study. European Journal of Clinical Pharmacology. 59(1). 57–64. 28 indexed citations
6.
Tamminga, Wim J., Johan Wemer, B. Oosterhuis, et al.. (2002). The prevalence of CYP2C19 genotypes in a population of healthy Dutch volunteers and apparent gender differences in phenotypes. British Journal of Clinical Pharmacology. 53(5). 2 indexed citations
7.
Tamminga, Wim J., et al.. (2001). The prevalence of CYP2D6 and CYP2C19 genotypes in a population of healthy Dutch volunteers. European Journal of Clinical Pharmacology. 57(10). 717–722. 81 indexed citations
8.
Stangier, Joachim, et al.. (2001). Inhibitory Effect of Telmisartan on the Blood Pressure Response to Angiotensin II Challenge. Journal of Cardiovascular Pharmacology. 38(5). 672–685. 36 indexed citations
9.
Tamminga, Wim J., et al.. (2001). An optimized methodology for combined phenotyping and genotyping on CYP2D6 and CYP2C19. European Journal of Clinical Pharmacology. 57(2). 143–146. 37 indexed citations
10.
Tamminga, Wim J., Johan Wemer, B. Oosterhuis, et al.. (2001). Mephenytoin as a probe for CYP2C19 phenotyping:effect of sample storage, intra‐individual reproducibility and occurrence of adverse events. British Journal of Clinical Pharmacology. 51(5). 471–474. 14 indexed citations
11.
Wieling, Jaap, et al.. (2000). Evaluation of analytical and clinical performance of a dual-probe phenotyping method for CYP2D6 polymorphism and CYP3A4 activity screening.. Therapeutic Drug Monitoring. 22(4). 486–496. 13 indexed citations
12.
Stangier, Joachim, Jochen Schmid, Dietrich Türck, et al.. (2000). Absorption, Metabolism, and Excretion of Intravenously and Orally Administered [14C]Telmisartan in Healthy Volunteers. The Journal of Clinical Pharmacology. 40(12). 1312–1322. 129 indexed citations
13.
Tamminga, Wim J., J. Wemer, B. Oosterhuis, et al.. (1999). CYP2D6 and CYP2C19 activity in a large population of Dutch healthy volunteers: indications for oral contraceptive-related gender differences. European Journal of Clinical Pharmacology. 55(3). 177–184. 107 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Deepak Gopal Shewade Breakdown of academic impact, for papers by SoJeong Yi Breakdown of academic impact, for papers by D. A. Flockhart Breakdown of academic impact, for papers by Chandrasekaran Adithan Breakdown of academic impact, for papers by William Schary Breakdown of academic impact, for papers by M.E.G. Naranjo Breakdown of academic impact, for papers by Peter M. Krahn Breakdown of academic impact, for papers by E. A. Sotaniemi Breakdown of academic impact, for papers by H.F. Woods Breakdown of academic impact, for papers by Boo Edgar
Rankless by CCL
2026